- Tytuł:
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- Autorzy:
- Źródło:
- In International Journal of Infectious Diseases February 2021 103:62-71
Czasopismo naukowe